Hims & Hers introduced Peptides+ on Wednesday, November 18, a program featuring five compounded treatments not approved by the FDA: sermorelin, glutathione, NAD+, vitamin B12, and L-carnitine, according to CNBC. The day prior, Noom debuted OpenRx, a standalone brand focused on peptides and preventive health, as reported by Fierce Healthcare.
These launches shift unapproved wellness products out of niche clinics and online “research” vendors and into two of the nation’s most recognized telehealth platforms. Hims alone serves roughly 2.8 million subscribers.
For consumers encountering ads focused on anti-aging, recovery, or sleep, the practical question has shifted. These products can now be prescribed through a licensed pharmacy, but that does not mean they have been proven safe or effective for the marketed uses.
Products Offered by Hims and Noom
Hims customers who complete a consultation with a licensed provider may receive a personalized plan incorporating the five products. The company’s Peptides+ page notes that the treatments are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. Sermorelin is used by some individuals to address the decline in growth hormone associated with aging, while glutathione is marketed for immune support.
The program’s protocols were developed under Dr. Anant Vinjamoori, chief medical officer for the Hims brand, who joined in June. Hims has said it plans to later add BPC-157 and TB-500—two injectable peptides popular for injury recovery—and manufacture them in the United States, according to Reuters. The company’s chief financial officer said peptide revenue is expected to be “immaterial through the year.”
Noom acquired its own pharmacy in April with the purchase of Tailor Made Compounding, a licensed 503A pharmacy operating across 46 states, according to Noom’s acquisition announcement. The pharmacy’s formulary already included compounded NAD+, sermorelin, topical GHK-Cu, and oxytocin. Hims owns a U.S. compounding pharmacy and a manufacturing facility it acquired in 2025. Pricing for the new products was not available at the time of publication.
Legal Framework Supporting the Launches
Compounding pharmacies may prepare unapproved drugs for an individual patient with a valid prescription under section 503A of federal drug law, subject to oversight by state pharmacy boards. The ingredients they may use depends on FDA lists that the agency has been revising this year.
In April, the FDA said it would remove 12 peptides from Category 2, its list of substances posing significant safety concerns, but removal alone did not authorize them for compounding, law firm Orrick explained. Then, on October 28, HHS Secretary Robert F. Kennedy Jr. announced an interim policy stating that regulators would not take action against compounders producing six peptides—BPC-157, epitalon, KPV, MOTS-c, Semax, and TB-500—provided they meet quality, prescription, and reporting conditions.
That policy relies on enforcement discretion and does not alter the law or add the peptides to the FDA’s list of approved bulk ingredients, according to an analysis by Science-Based Medicine. The five products launched by Hims this week are not among those six.
MedicalDaily previously covered the HHS policy upon its announcement, as well as the American Medical Association’s call to rescind it. Those stories examined the rules on paper. This week’s launches show how those rules appear in a shopping cart.
Limited Evidence and Safety Concerns
None of the five Hims products or the six peptides included in the HHS policy has been approved by the FDA for the anti-aging, recovery, or wellness uses being promoted. Critics have warned of contamination, impurities, and unknown side effects, and argue that peptides should undergo the standard approval process, according to Reuters.
Scott Gavura, a pharmacist and contributor to Science-Based Medicine, argued that HHS’s evidence for some peptides is asserted but not made public. He wrote that “without meaningful surveillance, the absence of observed harms should not be reassuring.”
Supporters, including Kennedy, argue that a regulated U.S. route is safer than purchasing products from overseas sellers labeled “research use only.” Both perspectives can be true. Improved manufacturing can reduce the risk of a contaminated vial, but it cannot demonstrate whether a product works or is safe over years of use.
Competitive athletes face a separate issue. Sermorelin and BPC-157 appear on the World Anti-Doping Agency’s prohibited list, so a prescription does not permit their use in tested sports.
Questions to Ask Before Starting a Peptide
Anyone offered one of these products can ask the prescriber what evidence supports the specific use, what side effects to watch for, and how long treatment is intended to last. It is also useful to ask which pharmacy will prepare the product and to confirm its state license.
Pregnant or breastfeeding individuals, people with a history of cancer, and those with hormone-sensitive conditions should exercise particular caution, as human safety data for many of these products remain limited. Anyone taking prescription medications can consult a pharmacist about potential interactions before adding a compounded product.
Because the products are not FDA-approved, insurance generally does not cover them, so buyers should expect to pay out of pocket and review subscription and cancellation terms.
Injection-site redness or swelling, a rash, fever, or other new symptoms should be reported to a clinician and to the FDA’s MedWatch program. Facial swelling or difficulty breathing requires emergency care. MedicalDaily will report on any FDA action regarding peptide compounding and on when Hims adds BPC-157 and TB-500.
Key Questions Answered
What did Hims & Hers launch? Peptides+, a program offering compounded sermorelin, glutathione, NAD+, vitamin B12, and L-carnitine following a provider visit.
What is Noom’s OpenRx? A standalone Noom brand for peptides and preventive health, supplied by the compounding pharmacy Noom acquired in April.
Are these products FDA-approved? No. They are compounded products that the FDA has not approved for these uses.
Is BPC-157 included? Not yet. Hims says it plans to add BPC-157 and TB-500 later.
Why can pharmacies make them? Compounding pharmacies can prepare unapproved drugs for individual prescriptions, and HHS has eased enforcement for six peptides.
Will insurance pay for them? Generally no. Buyers should expect to pay out of pocket.
Also Read
- Hone Health Raises $228 Million to Expand Personalized Longevity Care
- Two‑Year Results Sustain Clinical Benefits of Tau‑Targeted Diranersen in Alzheimer’s
- NIH to Retire Its Final Research Chimpanzees to Louisiana Sanctuary Next Year
- Neanderthal-Inherited DNA Segment Linked to Lower Schizophrenia Risk


